Our single mutant trastuzumab glycovariants conjugated with the anti-mitotic agent MMAE carried sufficient drug payload to achieve selective and efficient killing of HER2-expressing breast cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.